Literature DB >> 20824001

Development of Targeted Therapies in ErbB2-Positive Breast Cancer.

Christian Jackisch1, Josef Rüschoff, Axel Ullrich.   

Abstract

Entities:  

Year:  2008        PMID： 20824001      PMCID： PMC2930989          DOI： 10.1159/000119745

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  21 in total

Review 1.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

Authors:  N Prenzel; O M Fischer; S Streit; S Hart; A Ullrich
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

2.  Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.

Authors:  Yan Ma; Laurence Lespagnard; Virginie Durbecq; Marianne Paesmans; Christine Desmedt; Maria Gomez-Galdon; Isabelle Veys; Fatima Cardoso; Christos Sotiriou; Angelo Di Leo; Martine J Piccart; Denis Larsimont
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

Review 3.  Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

Authors:  I E Smith
Journal:  Anticancer Drugs       Date:  2001-12       Impact factor: 2.248

4.  Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

Authors:  Michael F Press; Guido Sauter; Leslie Bernstein; Ivonne E Villalobos; Martina Mirlacher; Jian-Yuan Zhou; Rooba Wardeh; Yong-Tian Li; Roberta Guzman; Yanling Ma; Jane Sullivan-Halley; Angela Santiago; Jinha M Park; Alessandro Riva; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

6.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Authors:  Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.

Authors:  Karen A Gelmon; John Mackey; Shailendra Verma; Stan Z Gertler; Nicholas Bangemann; Paul Klimo; Andreas Schneeweiss; Karl Bremer; Denis Soulieres; Katia Tonkin; Richard Bell; Bernhard Heinrich; Debjani Grenier; Reg Dias
Journal:  Clin Breast Cancer       Date:  2004-04       Impact factor: 3.225

9.  Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Authors:  Harold J Burstein; Lyndsay N Harris; P Kelly Marcom; Rosemary Lambert-Falls; Kathleen Havlin; Beth Overmoyer; Robert J Friedlander; Janet Gargiulo; Rochelle Strenger; Charles L Vogel; Paula D Ryan; Mathew J Ellis; Raquel A Nunes; Craig A Bunnell; Susana M Campos; Michele Hallor; Rebecca Gelman; Eric P Winer
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

10.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

Authors:  A L Schechter; M C Hung; L Vaidyanathan; R A Weinberg; T L Yang-Feng; U Francke; A Ullrich; L Coussens
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728
View more
  1 in total

Review 1.  The application of artificial intelligence in lung cancer: a narrative review.

Authors:  Huixian Zhang; Die Meng; Siqi Cai; Haoyue Guo; Peixin Chen; Zixuan Zheng; Jun Zhu; Wencheng Zhao; Hao Wang; Sha Zhao; Jia Yu; Yayi He
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.